A number of new therapeutics in development and in the marketplace, including 'checkpoint inhibitors,' suggest how a paradigm shift in therapeutic strategy is underway for many diseases and indications. The new strategy involves both a renormalization of physiology to treat the disease and a combination of molecule types, working on different pathways, often at different levels and tissues of the system, for example proteins and microbiota, to institute a systems therapeutic approach. This approach had been shown to be efficacious with few adverse side effects.
Editorial Maguire
and at multiple levels of the system using a systems therapeutics approach, enhances physiological renormalization, helping to quell the cancer.
Systems therapeutics for physiological renormalization was also successfully used by Mao-Qiang et al. [10] to develop a commercialized topical product containing multiple lipid types to mimic and restore barrier function of the skin's stratum corneum. As a result of restored barrier function, a reduction in skin and systemic inflammation associated with aged and other inflammatory conditions of the skin was found [11] . In this case, cholesterol, free fatty acids and ceramide are combined in a topical emollient that feeds the necessary lipids to keratinocytes so that multilamellar bodies are produced and excreted by the keratinocytes to rebuild the stratum corneum. The stratum corneum is responsible for the skin's barrier function that prevents moisture loss and protects from environmental insult. Dysfunction of the stratum corneum is associated with dermatosis, including atopic dermatitis [12] and may lead to an induction of chronic systemic inflammation [11] , a causal factor in many diseases.
Systems therapeutics for physiological renormalization is under development to treat neurodegenerative disease [2] , where the multiple types of molecules from stem cells and other cell types that surround and support neurons, was applied to damaged neurons for their rescue. Here again the approach is to use multiple molecule types at multiple levels of the system. This approach can quench the prion-like spread of misfolded, dysfunctional proteins and re-establish the matrix surrounding neurons so that endogenous signaling molecules from surrounding cells can use the matrix to shuttle from healthy cells to degenerating cells for purposes of neuronal rescue.
At the level of protein pathways, many natural molecular, cellular and tissue functions are initiated and maintained by protein level circuits. For example, caspase-mediated programmed cell death -that is, apoptosis -is orchestrated by a circuit of proteases that activate one another through cleavage [13] . A number of advantages are offered by targeting protein circuits offers as compared with targeting genetic circuits. These include quicker operation, direct coupling to endogenous pathways, single transcript delivery and function without genomic integration [14] . As such, therapeutics at the protein level could be very important for neurodegenerative diseases as the disease state may often occur at the protein level, not the genomic level [2] . Although genomic correlates have been demonstrated in an animal model of amyotrophic lateral sclerosis, transcripts were normal, suggesting that the disease state occurs at the level of protein translation or post-translation despite the association of some genetic defects [15] .
Many diseases, if not most, are a function of our exposome and not our genome, affecting many nongenomic pathways [4] . The fact that many nongenomic pathways are affected in diseases argues for using systems therapeutics to target those pathways. This may be a preferred strategy compared with targeted approaches that affect only one pathway, often doing so at the irrelevant target level of the genome. Using the systems therapeutic to institute physiological renormalization for disease remediation has proven efficacious for a number of disease states [2, 7, 8, 11] . The therapeutic strategy using systems therapeutics, especially when the multiple molecule types are bioidentical molecules, to induce physiological renormalization has been shown to be efficacious with few adverse side effects. This promising new therapeutic strategy, for which there are multiple lines of evidence [2, 7, 8, 11] , could have far-reaching implications for chronic diseases and indications and as a new means for therapeutic development.
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